Losartan, an angiotensin receptor blocker, has been effective in preventing the development
of emphysema and lung inflammation in animal models of COPD. Moreover, there is
epidemiologic evidence that suggests that this drug may be effective in reducing COPD
morbidity and mortality.
This study will provide treatment with either losartan or placebo for a period of 12 months
to determine whether there is progression of COPD as measured by high-resolution CT scans,
lung function, or blood tests for inflammation.
- Evidence of COPD by pulmonary function testing
- Clinical indication for angiotensin receptor blockers or ACE inhibitors
- Significant kidney disease or heart disease
- History of intolerance to losartan or similar drugs